Alkem Medtech updates Occlutech acquisition with supplementary agreement

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹5425.00

prior close

₹5502.00

announcement price

In-mkt

timing

Nifty Midcap 150market-0.3%+0.5% vs market

Pharmaceuticals peers, median of 165sector+0.1%+0.1% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.3

15m

-0.3

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-0.3+0.5+0.1+0.1

Next day

+2.8+0.1+2.7+0.9+1.8

+2.5+0.3+2.2+0.3+2.2

+1.4+0.8+0.6+0.8+0.6

+2.8+0.6+2.2+1.7+1.1

+3.2+1.0+2.2+1.5+1.7

+3.6-0.9+4.5+0.1+3.5

15d

+4.2+1.5+2.7+1.8+2.4

+4.8+1.6+3.2+1.6+3.3

-1.8+3.5-5.2+1.3-3.1

-3.2-3.9+0.7+4.8-8.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Medtech, wholly owned subsidiary of Alkem Labs, has signed a First Supplementary Agreement on 26 June 2026 to the Share Purchase Agreement dated 6 March 2026, for acquiring at least 51 percent and up to 55 percent equity in Switzerland-based Occlutech Holding AG. This continues earlier disclosures from February and March 2026 on the medtech acquisition.

Likely market impact

Deal progresses as planned, supporting Alkem's move into medtech; final terms and completion still pending.